12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Clinical News  |  Regulatory

Grazax regulatory update

EC approved Grazax to treat grass-pollen induced hay fever in children and adolescents ages 5 to 17...

Read the full 61 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >